Literature DB >> 1393157

Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behaviour therapy.

E B Foa1, M J Kozak, G S Steketee, P R McCarthy.   

Abstract

The efficacy of behavioural treatment of obsessive-compulsive disorder (OCD) has been well documented. However, severely depressed OCD patients showed fewer short- and long-term benefits than less depressed patients. The present study tested the hypothesis that reduction of depression by imipramine prior to behaviour therapy would enhance the effects of behavioural therapy on depressed OC patients. Thirty-eight patients were divided into highly and mildly depressed groups according to their scores on the Beck Depression Inventory; half of each group received imipramine and half received placebo for six weeks. All patients then received three weeks of daily behavioural treatment (exposure and response prevention) followed by 12 weekly sessions of supportive psychotherapy. Results indicated that although imipramine improved depressive symptoms in depressed patients, it did not affect OC symptoms. Behaviour therapy markedly reduced OC symptoms but, contrary to our hypothesis, imipramine did not potentiate the effects of behaviour therapy. No differences between highly depressed and mildly depressed patients on OC symptoms were found in their responses to behavioural or supportive therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1393157     DOI: 10.1111/j.2044-8260.1992.tb00995.x

Source DB:  PubMed          Journal:  Br J Clin Psychol        ISSN: 0144-6657


  12 in total

1.  Predicting course of illness in patients with severe obsessive-compulsive disorder.

Authors:  Sarah L Garnaat; Christina L Boisseau; Agustin Yip; Nicholas J Sibrava; Benjamin D Greenberg; Maria C Mancebo; Nicole C R McLaughlin; Jane L Eisen; Steven A Rasmussen
Journal:  J Clin Psychiatry       Date:  2015-12       Impact factor: 4.384

2.  The impact of symptom dimensions on outcome for exposure and ritual prevention therapy in obsessive-compulsive disorder.

Authors:  Monnica T Williams; Samantha G Farris; Eric N Turkheimer; Martin E Franklin; H Blair Simpson; Michael Liebowitz; Edna B Foa
Journal:  J Anxiety Disord       Date:  2014-06-14

3.  Change in obsessive-compulsive symptoms mediates subsequent change in depressive symptoms during exposure and response prevention.

Authors:  Laurie J Zandberg; Yinyin Zang; Carmen P McLean; Rebecca Yeh; Helen Blair Simpson; Edna B Foa
Journal:  Behav Res Ther       Date:  2015-03-13

4.  Longitudinal course of obsessive-compulsive disorder in patients with anxiety disorders: a 15-year prospective follow-up study.

Authors:  Brook A Marcks; Risa B Weisberg; Ingrid Dyck; Martin B Keller
Journal:  Compr Psychiatry       Date:  2011-02-23       Impact factor: 3.735

Review 5.  Cognitive behavioral therapy for obsessive-compulsive disorder: an update.

Authors:  Jonathan D Huppert; Martin E Franklin
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

Review 6.  Minority participation in randomized controlled trials for obsessive-compulsive disorder.

Authors:  Monnica Williams; Mark Powers; Yeo-Gin Yun; Edna Foa
Journal:  J Anxiety Disord       Date:  2010-03

Review 7.  Symptom dimensions in obsessive-compulsive disorder: phenomenology and treatment outcomes with exposure and ritual prevention.

Authors:  Monnica T Williams; Beth Mugno; Martin Franklin; Sonya Faber
Journal:  Psychopathology       Date:  2013-04-20       Impact factor: 1.944

8.  Treatment of obsessive-compulsive disorder complicated by comorbid eating disorders.

Authors:  H Blair Simpson; Chad T Wetterneck; Shawn P Cahill; Joanna E Steinglass; Martin E Franklin; Rachel C Leonard; Theodore E Weltzin; Bradley C Riemann
Journal:  Cogn Behav Ther       Date:  2013-01-15

9.  Current diagnosis and treatment of anxiety disorders.

Authors:  Alexander Bystritsky; Sahib S Khalsa; Michael E Cameron; Jason Schiffman
Journal:  P T       Date:  2013-01

Review 10.  Obsessive-compulsive disorder in elderly patients.

Authors:  C W Jackson
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.